Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive.
Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici for $1.48 billion in April. Both companies were co-founded by serial entrepreneur Cathal Friel.
Poolbeg, which was spun out of Open Orphan (now Hvivo), in 2021, is targeting the growing infectious disease market.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
